Arrowhead Pharmaceuticals Other Current Liabilities

Arrowhead Pharmaceuticals (ARWR) currently reports a other current liabilities of $120M as of June 2026. That compares with $130M in the prior-year period — down 8.0% year over year. Use the charts on this page to explore Arrowhead Pharmaceuticals's other current liabilities history and peer comparisons.

Arrowhead Pharmaceuticals's other current liabilities decreased from $130M to $120M — a 8.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arrowhead Pharmaceuticals reported $120M in other current liabilities as of June 2026. That compares with $130M in the prior-year period — down 8.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Arrowhead Pharmaceuticals, and consider following ARWR for alerts when major investors trade the stock.

Arrowhead Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $120M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARWR with unrelated industries.